Author

B. Agerer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 2 Approach:statistical model· 2 Organism:virus· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. Bergthaler· 6 shared C. Bock· 4 shared A. Lercher· 3 shared A. Popa· 3 shared L. Endler· 3 shared M. Smyth· 3 shared A. Hladik· 2 shared A. Zoufaly· 2 shared

Activity by Year

2018-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

A. Bergthaler

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Nuclear receptor corepressor 1 controls regulatory T cell subset differentiation and effector function

V. Stolz, R. de Freitas e Silva, R. Rica, C. Zhu, T. Preglej, P. Hamminger, D. Hainberger, M. Alteneder, L. Müller, M. Waldherr, D. Waltenberger, A. Hladik, B. Agerer, M. Schuster, T. Frey, , W. Ellmeier

This study shows NCOR1 regulates Treg cell differentiation and suppressive function by maintaining transcriptional integrity in both naive and effector states.

eLife · Oct 28, 2024Peer-reviewedImmunology

ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology

R. Gawish, P. Starkl, L. Pimenov, A. Hladik, K. Lakovits, F. Oberndorfer, S. J. F. Cronin, A. Ohradanova-Repic, G. Wirnsberger, B. Agerer, L. Endler, T. Capraz, J. W. Perthold, A. Hagelkruys, N. Montserrat, , S. Knapp

This paper develops a mouse-adapted SARS-CoV-2 strain, maVie16, to model COVID-19 in mice, showing that ACE2 is critical for disease and that blocking TNF/IFNγ reduces immunopathology.

bioRxiv · Aug 9, 2021Immunology

SARS-CoV-2 escapes CD8 T cell surveillance via mutations in MHC-I restricted epitopes

B. Agerer, M. Koblischke, V. Gudipati, M. Smyth, A. Popa, J.-W. Genger, L. Endler, D. M. Florian, V. Muehlgrabner, A. Lercher, P. Gattinger, R. Torralba-Gombau, T. Penz, I. Fae, S. Wenda, , A. Bergthaler

The paper identifies mutations in SARS-CoV-2 that reduce MHC-I binding and CD8+ T cell recognition, suggesting escape from immune surveillance.

bioRxiv · Dec 18, 2020 · PreprintImmunology

Mutational dynamics and transmission properties of SARS-CoV-2 superspreading events in Austria

A. Popa, J.-W. Genger, M. Nicholson, T. Penz, D. Schmid, S. W. Aberle, B. Agerer, A. Lercher, L. Endler, H. Colaco, M. Smyth, M. Schuster, M. Grau, F. Martinez Jimenez, O. Pich, , A. Bergthaler

This study analyzes SARS-CoV-2 superspreading events in Austria using genomic and epidemiological data to understand viral transmission and mutation dynamics.

Science Translational Medicine · Dec 9, 2020Peer-reviewedMicrobiology

A systematic genetic interaction map of human solute carriers assigns a role to SLC25A51/MCART1 in mitochondrial NAD uptake

E. Girardi, G. Fiume, U. Goldmann, C. Sin, F. Mueller, S. Lindinger, V. Sedlyarov, I. Srndic, B. Agerer, F. Kartnig, E. Meixner, A. Skucha, M. Rebsamen, A. Bergthaler, J. Menche, G. Superti-Furga

The paper systematically maps genetic interactions among human solute carriers, identifying SLC25A51/MCART1 as a mitochondrial NAD(H) transporter.

bioRxiv · Aug 31, 2020 · PreprintCell Biology

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

L. Kosack, B. Wingelhofer, A. Popa, B. Vilagos, A. Orlova, P. Majek, K. Parapatics, A. Lercher, B. Agerer, A. Ringler, J. Klughammer, M. Smyth, K. Khamina, H. Baazim, D. A. Rosa, , A. Bergthaler

This study identifies the ERBB-STAT3 axis as a driver of Tasmanian devil facial tumor disease and proposes a dual chemo-immunotherapeutic strategy.

bioRxiv · Apr 12, 2018Cancer Biology